New hope for tough-to-treat colorectal cancer: combo therapy enters human testing
NCT ID NCT07229872
First seen Nov 17, 2025 · Last updated May 25, 2026 · Updated 30 times
Summary
This early-phase study tests a combination of two drugs—aipalirovorelizumab (QL1706) and fruquintinib—in 18 adults with advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if the combination can shrink tumors or slow disease progression. Participants receive the drugs intravenously and orally in 3-week cycles until the disease worsens or side effects become too severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.